Henry W B Johnson - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Henry W B Johnson

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

The Journal of Pharmacology and Experimental Therapeutics|July 16, 2025

Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activityEric Lowe, Janet L Anderl, David Bade, et al.

Journal of Medicinal Chemistry|May 3, 2012

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.

Bioorganic & Medicinal Chemistry Letters|November 7, 2012

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitorsTimothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

The Journal of Pharmacology and Experimental Therapeutics|July 16, 2025

Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activityEric Lowe, Janet L Anderl, David Bade, et al.

Journal of Medicinal Chemistry|May 3, 2012

Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitorsJames W Leahy, Chris A Buhr, Henry W B Johnson, et al.

Bioorganic & Medicinal Chemistry Letters|November 7, 2012

SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitorsTimothy Forsyth, Patrick C Kearney, Byung Gyu Kim, et al.

Pageof 2